Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation, Published online: 10 February 2024; doi:10.1038/s41409-024-02234-1Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 10, 2024 Category: Hematology Authors: Ryusuke Yamamoto Nobuhiro Hiramoto Ayumi Fujimoto Hirohito Yamazaki Takehiko Mori Naoyuki Uchida Noriko Doki Jun Kato Masashi Nishikubo Shinichi Kako Tetsuya Nishida Shuichi Ota Makoto Onizuka Tetsuya Eto Koichi Onodera Kazuhiro Ikegame Ken-ichi Matsuoka Source Type: research
Aplastic anemia: history and recent developments in diagnosis and treatment
Int J Hematol. 2024 Feb 4. doi: 10.1007/s12185-024-03715-1. Online ahead of print.ABSTRACTAcquired aplastic anemia is an immune-mediated disease that targets hematopoietic stem cells, which is diagnosed by findings of peripheral blood pancytopenia and hypocellular bone marrow. Although the diagnostic definition is simple, differential diagnosis from other overlapping hematopoietic disorders such as hypoplastic myelodysplastic syndrome and inherited bone marrow failure syndrome is not easy. Immune suppressive therapy and allogeneic hematopoietic stem cell transplantation are important treatment approaches for aplastic anemi...
Source: International Journal of Hematology - February 3, 2024 Category: Hematology Authors: Yasushi Onishi Source Type: research
Loeys-Dietz syndrome with concomitant aplastic anemia
(Source: Annals of Hematology)
Source: Annals of Hematology - February 2, 2024 Category: Hematology Source Type: research
The outcome and predictive model of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia from the Chinese Blood and Marrow Transplant Registry Group
Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.284581. Online ahead of print.ABSTRACTNot available.PMID:38299673 | DOI:10.3324/haematol.2023.284581 (Source: Haematologica)
Source: Haematologica - February 1, 2024 Category: Hematology Authors: Zheng-Li Xu Lan-Ping Xu Yi-Cheng Zhang Yu-Hong Zhou Er-Lie Jiang Jian-Ping Zhang Bin Fu Gui-Fang Ouyang Xian-Min Song Xue-Jun Zhang Yu-Jun Dong Nai-Nong Li Ling Wang Xi Zhang Peng-Cheng He Fan-Sheng Kong Hui-Xia Liu Li Liu Lin Liu Tai-Wu Xiao Wen-Wei Xu X Source Type: research
Self-Reported Late Effects and Quality of Life (QOL) of Long-Term Survivors of Severe Aplastic Anemia Who Have Undergone Allogeneic Hematopoietic Cell Transplant (HCT)
With improved outcomes of patients who have undergone allogeneic HCT for severe aplastic anemia (SAA) there is a growing population of survivors. However, current literature lacks details regarding late effects that occur in these survivors. Additionally, with increasing use of alternative donors for SAA, it is important to compare their late effects and quality of life (QOL) by donor type. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Neel S. Bhatt, Lynn Onstad, Dr. Paul A. Carpenter, Catherine J. Lee, Rohtesh S. Mehta, Masumi Ueda, Phuong Vo, K. Scott Baker, Stephanie J. Lee Tags: 474 Source Type: research
Long-Term Follow-up of Outcomes of Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia: A Single Center Retrospective Review Spanning More Than 25 Years.
We report our single center experience, including long term follow-up, of 111 pediatric patients with SAA who underwent HSCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Jay A. Read, Megha Thakkar, Ghadir Sasa, Saleh Bhar, John Craddock, Erin E Doherty, Anil George, Gabriela Llaurador, Erin A Morales, Baheyeldin Salem, David H.M. Steffin, Khaled Yassine, Alison Bertuch, Robert A. Krance, Caridad Martinez Tags: 396 Source Type: research
Tcr αβ-Depleted Haploidentical Hematopoietic Cell Transplantation for Pediatric Patients with Severe Aplastic Anemia
We evaluated the outcome of haploidentical hematopoietic cell transplantation (haplo-HCT) using an ex vivo TCR αβ-depleted graft in pediatric patients with acquired severe aplastic anemia (SAA). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ho Joon Im, Sung Han Kang Tags: 324 Source Type: research
Excellent Outcome Following Haplo-Identical and Unrelated Donor HSCT for Young Patients with Sever Aplastic Anemia Using Reduced Dose TBI and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis
Severe aplastic anemia (SAA) is a potentially fatal hematologic disorder that can be cured with hematopoietic stem cell transplantation (HSCT). Although the outcomes with HLA-identical siblings are favorable, the majority of patients lack suitable HLA-identical donors. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ayad Ahmed Hussein, Clinton Carroll, Noor Awni Ghanem, Bayan Majed Alaraj, Jennifer Domm, Tariq Ahmed Abdelghani, Meghann McManus, Dina Mohammad Abu Assab, Hadeel Hassan Alzoubi, Misty Evans, Haydar Frangoul Tags: 213 Source Type: research
Favorable Outcomes in Severe Aplastic Anemia Patients Undergoing Allo-HSCT with Fludarabine, Cyclophosphamide, and ATG Conditioning
Matched sibling donor (MSD) allogenic stem cell transplantation (allo-HSCT) is the standard of care curative treatment for young, fit patients with severe aplastic anemia (SAA). Several conditioning regimens have been studied, with Fludarabine (Flu)/Cyclophosphamide (Cy)/Anti-thymocyte globulin (ATG) or Cy/ATG demonstrating the best survival outcomes. Previous research reported 5-year survival probabilities of 91% for Flu/Cy/ATG, 91% for Cy/ATG, 80% for Cy ± Flu, and 84% for Bu/Cy (Bejanyan et al., 2019). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Reem Alasbali, Riad El Fakih, Ahmed Kotb Abdrabou, Naeem Chaudhri, Saud Alhayli, Fahad Alsharif, Amr Hanbali, Feras Alfraih, Marwan Shaheen, Mansour Alfayez, Alfadel Alshaibani, Abdulwahab Albabtain, Ahmad Alotaibi, AymanTusneem A SaadElhassan, Hadeel Sam Tags: 208 Source Type: research
Outcomes of Matched Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation in Aplastic Anemia: A Systematic Review and Meta-Analysis
Immunosuppressive therapy and matched-related allogenic hematopoietic stem cell transplantation (HCT) are considered standard treatment for severe aplastic anemia (AA). When a fully matched sibling donor (MSD) is unavailable, a matched unrelated donor (MUD) or haploidentical HCT is an alternative approach. This systematic review and meta-analysis aimed to explore the outcomes of MUD or haploidentical HCT in severe AA. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Moazzam Shahzad, Ahmad Basharat, Muhammad Fareed Khalid, Jawad Noor, Salman J Khan, Muftah Mahmud, Muhammad Kashif Amin, Ammad Naeem, Iqra Anwar, Mohammad Ammad Ud Din, Michael V Jaglal Tags: 194 Source Type: research
Monoallelic Germline Pathogenic Variants in DNA Damage Repair Genes and Their Impact on Post-Hematopoietic Cell Transplantation Outcomes in Severe Aplastic Anemia
Recipients of HCT are under significant stressors that may predispose them to DNA damage and unfavorable outcomes. Patients with inherited defects in DNA damage response or repair (DDRR), such as Fanconi anemia, need special conditioning regimens to minimize toxicity. HCT outcomes in patients carrying pathogenic or likely pathogenic (P/LP) variants in DDRR genes is unknown. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Maryam Rafati, Youjin Wang, Lisa J. McReynolds, Kristine Jones, Belynda Hicks, Stephen R. Spellman, Meilun He, Yung-Tsi Bolon, Stephanie J. Lee, Sharon A. Savage, Shahinaz M. Gadalla Tags: 75 Source Type: research
Mimicking pneumonia with septic shock: A case report and literature review
Exp Ther Med. 2023 Dec 20;27(2):73. doi: 10.3892/etm.2023.12361. eCollection 2024 Feb.ABSTRACTHydrochlorothiazide (HCTZ) is a commonly used diuretic antihypertensive drug that can cause electrolyte disorders, hyperglycemia and hyperuricemia as well as rare life-threatening adverse drug reactions. These include non-cardiogenic pulmonary edema, interstitial pneumonia, angioedema and aplastic anemia. The present report describes a case of a 59-year-old man who developed a hypersensitivity reaction to HCTZ. Specifically, the patient presented with symptoms of cough, chest tightness and shortness of breath, with pneumonic conso...
Source: Experimental and Therapeutic Medicine - January 24, 2024 Category: General Medicine Authors: Yufang Guo Qiuqi Lin Zexu Wang Ping Zhan Liangquan Wu Xia Pan Xiuwei Zhang Li Wang Bing Wan Source Type: research
Inherited bone marrow failure syndromes: phenotype as a tool for early diagnostic suspicion at a major reference center in Mexico
Conclusions: Thorough examination of reported clinical data allowed us to highly suspect a specific IBMFS in approximately 70% of patients; however, an important number of patients remained with suspicion of an undefined IBMFS. Implementation of NGS and telomere length measurement are forthcoming measures to improve IBMFS diagnosis in Mexico. (Source: Frontiers in Genetics)
Source: Frontiers in Genetics - January 24, 2024 Category: Genetics & Stem Cells Source Type: research
Upfront umbilical cord blood transplantation versus immunosuppressive therapy for pediatric patients with idiopathic severe aplastic anemia
Acquired severe aplastic anemia (SAA) is a rare, life-threatening disorder characterized by severe progressive pancytopenia mediated by autoimmunity attack on hematopoietic stem and progenitor cells1. The upfront therapy option for SAA is either an allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a human leukocyte antigen (HLA)-matched sibling donor or IST based on the patient's age, comorbidities, and donor availability2. For newly diagnosed children and adolescents with SAA, the standard IST with horse anti-thymocyte globulin (ATG) and cyclosporine (CSA) are often started when an MSD is not available2....
Source: Biology of Blood and Marrow Transplantation - January 24, 2024 Category: Hematology Authors: Xuxu Zhao, Wenxiu Lv, Kaidi Song, Wen Yao, Chun Li, Baolin Tang, Xiang Wan, Liangquan Geng, Guangyu Sun, Ping Qiang, Huilan Liu, Hongjun Liu, Zimin Sun Source Type: research
Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study
ConclusionsLetermovir effectively prevents CMV infection in allo-HSCT recipients with AA and demonstrates a high safety profile. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 24, 2024 Category: Infectious Diseases Source Type: research
